reports
- Jacob Mekhael
Onward Medical Uneventful 3Q25 results, pivotal Empower BP trial to st...
Onward reported its 3Q25 results, which show no major surprises as the company previously announced the sale of 40 devices in the US in a preliminary update. With a cash position of € 77.7m, Onward is funded into 1Q27 assuming no drawdown of its debt facility. In the pipeline, timelines were reiterated and the company continues to expect to initiate the pivotal Empower BP trial of the ARC-IM system in blood pressure instability by YE25, which means interim results could come in 2H26. We reiterat...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thibault Leneeuw
- Wim Lewi
ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important...
ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025 EINDHOVEN, the Netherlands, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announced its results for the third quarter of 2025 and provides a comprehensive business update: Commercial traction: The Company met its objective of 40 ARC-EX® Systems ...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
- Mathijs Geerts Danau
Onward Medical ARC-EX US home use label expansion broadens commercial ...
Onward announced that it has received 510(k) clearance to expand the ARC-EX system indication for home use in SCI patients in the US. This follows the initial approval for clinic use obtained in 4Q24, and we believe this expansion could unlock sales beyond rehabilitation clinics and to individual patients, which in our view is key to broaden the commercial potential of the ARC-EX system. With 70 devices sold in 9M25, we believe FY25 CSS of 150 devices sold is within reach, and look forward to ne...
ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System I...
ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication for Home Use THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) US FDA clearance now allows use of the ARC-EX® System both in clinics and homesARC-EX is the first and only FDA-cleared technology demonstrated to improve hand strength and sensation in people with spinal cord injuryYear to date, ARC-EX Systems have been purchased by more than 60 US clinics EINDHOVEN, the Netherlands, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ONWARD Medic...
ONWARD Medical Publishes Closing of Bookbuild Offering
ONWARD Medical Publishes Closing of Bookbuild Offering NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR:...
- Jacob Mekhael
Onward Medical Raises € 50.85m gross proceeds in private placement
Onward announced the placement of 11.3m new ordinary shares in a private placement by way of an accelerated bookbuild offering at an issue price of € 4.5 per share (approx. 12.5% discount to closing price prior to deal announcement) resulting in gross proceeds of € 50.85m. Onwards cash runway is extended through at least end of 2026 (previously 1H26), assuming no drawdown of the company's debt facility with Runway Growth. The transaction was supported by existing and new, long-only and sector sp...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Wim Hoste
- Wim Lewi
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Incr...
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Successful transaction supported by strong demand from existing and new high-quality, lon...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Onward Medical Launches capital increase for gross proceeds of € 50m
Onward announced the launch of a capital increase by way of a bookbuild offering through a private placement with institutional investors intending to raise gross proceeds of approx. € 50m. The capital raise is expected to be anchored by multiple long-only institutions, including existing and new shareholders. Onward expects to use the net proceeds towards development of the implantable ARC-IM system (40%) and to support commercialisation of the external ARC-EX device in upper limb function in S...
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR ...
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 50 Million NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Private placement is expected to be anchored by multiple long-only institutions, in...
- Jacob Mekhael
Onward Medical Preliminary 3Q25 update shows ARC-EX US commercialisati...
Onward reported a preliminary 3Q25 update, which shows that ARC-EX commercialisation in the US remains on track. With 40 ARC-EX systems sold in the US in 3Q25 (20 systems in 2Q25), we believe FY25 consensus of 150 devices is within reach if this rate of uptake continues for the remainder of the year. Looking ahead, the company previously guided it anticipates home use label expansion for ARC-EX in the US, and plans to initiate the pivotal Empower BP trial of the implantable ARC-IM system in SCI ...
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accele...
ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States EINDHOVEN, the Netherlands, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces the following key achievements in the third quarter of 2025: Commercial traction: 40 ARC-EX® Systems were sold in Q3, demonstrating continued strong commercial traction...
Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical w...
Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20 EINDHOVEN, the Netherlands, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces that BNP Paribas’ broker Portzamparc has initiated coverage with a Buy rating and a Target Price of EUR 10.20. Dave Marver, Chief Executive Officer of ONWARD Medical...
Portzamparc – Groupe BNP Paribas initie la couverture d’ONWARD Medical...
Portzamparc – Groupe BNP Paribas initie la couverture d’ONWARD Medical avec une recommandation d’Achat et un objectif de cours de 10,20 EUR EINDHOVEN, Pays-Bas, 08 oct. 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société leader dans le domaine des neurotechnologies visant au développement de thérapies innovantes destinées à la restauration du mouvement, des fonctions et de l’indépendance chez les personnes atteintes d’une lésion de la moelle épinière ou d’autres troubles du mouvement, annonce aujourd’hui que Portzamparc – Groupe BNP Paribas a initié la couverture du ti...
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
- Jacob Mekhael
Onward Medical Publishes ARCIM data on blood pressure regulation in Na...
Onward announced two publications of detailed results from the clinical feasibility studies of ARC-IM therapy in blood pressure regulation in Nature and Nature Medicine. The publications build on the previously reported interim results, and continue to highlight the benefit of the ARC-IM system for SCI patients that have blood pressure instability. Note that ARC-IM for blood pressure instability is the next in line indication for Onward, where a pivotal (Empower BP) study is due to start by YE25...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.